PURPOSE: The Boston keratoprosthesis has had variable success rates in the past. However, significant modifications to design and management have recently led to successful outcomes. This study was undertaken to evaluate the outcomes of the Boston type 1 keratoprosthesis at our institution. METHODS: A retrospective chart review was performed of all Boston type 1 keratoprosthesis procedures conducted at a single practice at the New York Eye and Ear Infirmary from December 2006 to August 2010. Outcome measures included visual acuity, retention rates, and complications. RESULTS: In all, 58 eyes of 51 patients who received a Boston type 1 keratoprosthesis were included. The most common indication for the keratoprosthesis was failed penetrating keratoplasty (PK) (81.0%; mean 2.4±1.3 PKs per eye). Glaucoma was the most common comorbidity (75.9%). Pre-operative best corrected visual acuity (BCVA) was <20/400 in 87.9% of eyes. At last follow-up, 43.1% of eyes had a BCVA of 20/200. Retention rate was 87.9% over an average follow-up of 21.5±11.4 months (median 22 months, range 3-47 months). Complications increased with time, with 65.5% of eyes experiencing at least one event by 6 months and 75.9% by 1 year. The most common post-operative complication was retroprosthetic membrane formation (50.0%). CONCLUSIONS: The Boston type 1 keratoprosthesis provides visual recovery for eyes with multiple PK failures or with poor prognosis for primary PK, showing excellent retention rates. However, there is a trend towards a decline in visual acuity with time and the development of late complications, highlighting a need for longer-term studies.
PURPOSE: The Boston keratoprosthesis has had variable success rates in the past. However, significant modifications to design and management have recently led to successful outcomes. This study was undertaken to evaluate the outcomes of the Boston type 1 keratoprosthesis at our institution. METHODS: A retrospective chart review was performed of all Boston type 1 keratoprosthesis procedures conducted at a single practice at the New York Eye and Ear Infirmary from December 2006 to August 2010. Outcome measures included visual acuity, retention rates, and complications. RESULTS: In all, 58 eyes of 51 patients who received a Boston type 1 keratoprosthesis were included. The most common indication for the keratoprosthesis was failed penetrating keratoplasty (PK) (81.0%; mean 2.4±1.3 PKs per eye). Glaucoma was the most common comorbidity (75.9%). Pre-operative best corrected visual acuity (BCVA) was <20/400 in 87.9% of eyes. At last follow-up, 43.1% of eyes had a BCVA of 20/200. Retention rate was 87.9% over an average follow-up of 21.5±11.4 months (median 22 months, range 3-47 months). Complications increased with time, with 65.5% of eyes experiencing at least one event by 6 months and 75.9% by 1 year. The most common post-operative complication was retroprosthetic membrane formation (50.0%). CONCLUSIONS: The Boston type 1 keratoprosthesis provides visual recovery for eyes with multiple PK failures or with poor prognosis for primary PK, showing excellent retention rates. However, there is a trend towards a decline in visual acuity with time and the development of late complications, highlighting a need for longer-term studies.
Authors: David C Ritterband; Daniel Shapiro; Valeriya Trubnik; Michael Marmor; Seth Meskin; John Seedor; Jeffrey M Liebmann; Celso Tello; Richard Koplin; Noga Harizman; Uri Shabto; Robert Ritch Journal: Cornea Date: 2007-10 Impact factor: 2.651
Authors: Hall F Chew; Brandon D Ayres; Kristin M Hammersmith; Christopher J Rapuano; Peter R Laibson; Jonathan S Myers; Ya-Ping Jin; Elisabeth J Cohen Journal: Cornea Date: 2009-10 Impact factor: 2.651
Authors: Esen Karamursel Akpek; Mona Harissi-Dagher; Robert Petrarca; Salim I Butrus; Roberto Pineda; James V Aquavella; Claes H Dohlman Journal: Am J Ophthalmol Date: 2007-06-04 Impact factor: 5.258
Authors: Jonathan L Hager; David L Phillips; Kenneth M Goins; Anna S Kitzmann; Mark A Greiner; Alex W Cohen; Jeffrey D Welder; Michael D Wagoner Journal: Int Ophthalmol Date: 2015-05-16 Impact factor: 2.031
Authors: Maria Fideliz de la Paz; Josef Stoiber; Valeria de Rezende Couto Nascimento; Juan Alvarez de Toledo; Orang Seyeddain; Wolfgang Hitzl; Günther Grabner; Rafael I Barraquer; Ralph Michael Journal: Graefes Arch Clin Exp Ophthalmol Date: 2013-10-25 Impact factor: 3.117
Authors: Alja Crnej; Masahiro Omoto; Thomas H Dohlman; John M Graney; Claes H Dohlman; Brigita Drnovsek-Olup; Reza Dana Journal: Invest Ophthalmol Vis Sci Date: 2014-05-15 Impact factor: 4.799
Authors: Mohsin H Ali; Mark S Dikopf; Anthony G Finder; Ahmad A Aref; Thasarat Vajaranant; Jose de la Cruz; Maria Soledad Cortina Journal: Cornea Date: 2018-05 Impact factor: 2.651